trending Market Intelligence /marketintelligence/en/news-insights/trending/yitaes03fxensa-p5dqohg2 content esgSubNav
In This List

Concordia International to become Advanz Pharma after recapitalization

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Concordia International to become Advanz Pharma after recapitalization

Concordia International Corp. is changing its name to Advanz Pharma following its recapitalization.

In September, Concordia completed its recapitalization, reducing the company's outstanding debt by about $2.4 billion.

With the new Advanz Pharma brand, the company aims to bring sustainable value to customers, healthcare providers and patients through its portfolio of specialty generic as well as legacy branded, off-patent medicines.

The Canadian specialty pharmaceutical company's name change is expected to be effective in the fourth quarter, pending customary approvals, including stock exchange and shareholder approvals.